Prime Capital Investment Advisors LLC Buys New Stake in Valeant Pharmaceuticals International Inc (VRX)

Prime Capital Investment Advisors LLC bought a new position in shares of Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSE:VRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,835 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000.

A number of other institutional investors also recently bought and sold shares of VRX. Greenleaf Trust grew its position in shares of Valeant Pharmaceuticals International by 21.3% during the 4th quarter. Greenleaf Trust now owns 17,054 shares of the specialty pharmaceutical company’s stock valued at $354,000 after acquiring an additional 3,000 shares during the period. CIBC Asset Management Inc grew its position in shares of Valeant Pharmaceuticals International by 3.2% during the 4th quarter. CIBC Asset Management Inc now owns 124,559 shares of the specialty pharmaceutical company’s stock valued at $2,607,000 after acquiring an additional 3,837 shares during the period. Iron Financial LLC grew its position in shares of Valeant Pharmaceuticals International by 37.8% during the 4th quarter. Iron Financial LLC now owns 16,394 shares of the specialty pharmaceutical company’s stock valued at $341,000 after acquiring an additional 4,500 shares during the period. Janney Montgomery Scott LLC grew its position in shares of Valeant Pharmaceuticals International by 33.7% during the 3rd quarter. Janney Montgomery Scott LLC now owns 20,095 shares of the specialty pharmaceutical company’s stock valued at $288,000 after acquiring an additional 5,069 shares during the period. Finally, MML Investors Services LLC grew its position in shares of Valeant Pharmaceuticals International by 15.5% during the 4th quarter. MML Investors Services LLC now owns 40,581 shares of the specialty pharmaceutical company’s stock valued at $843,000 after acquiring an additional 5,431 shares during the period. Institutional investors own 50.10% of the company’s stock.

How to Become a New Pot Stock Millionaire

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Thursday, March 8th. The stock was acquired at an average cost of $15.34 per share, with a total value of $153,400.00. Following the completion of the acquisition, the director now owns 106,062 shares of the company’s stock, valued at $1,626,991.08. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Paulson bought 7,066,629 shares of Valeant Pharmaceuticals International stock in a transaction dated Tuesday, March 6th. The stock was acquired at an average cost of $15.40 per share, with a total value of $108,826,086.60. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 7,121,629 shares of company stock valued at $109,702,487. 11.54% of the stock is owned by corporate insiders.

Shares of Valeant Pharmaceuticals International stock traded down $0.85 during trading on Monday, hitting $15.07. 7,802,348 shares of the stock were exchanged, compared to its average volume of 12,413,860. The stock has a market cap of $5,553.54, a P/E ratio of 3.93, a price-to-earnings-growth ratio of 0.33 and a beta of -0.32. Valeant Pharmaceuticals International Inc has a 12-month low of $8.31 and a 12-month high of $24.43. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 4.25.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Valeant Pharmaceuticals International had a net margin of 27.56% and a return on equity of 42.48%. The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.18 billion. During the same period in the previous year, the company earned $1.26 EPS. The company’s revenue for the quarter was down 10.0% on a year-over-year basis. sell-side analysts forecast that Valeant Pharmaceuticals International Inc will post 3.12 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on VRX. Mizuho raised their price target on shares of Valeant Pharmaceuticals International from $7.00 to $10.00 and gave the company an “underperform” rating in a research note on Friday, December 15th. Zacks Investment Research raised shares of Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright reissued a “hold” rating and issued a $16.00 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, March 15th. ValuEngine lowered shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Wells Fargo reissued a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, March 20th. Six equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $18.30.

TRADEMARK VIOLATION NOTICE: “Prime Capital Investment Advisors LLC Buys New Stake in Valeant Pharmaceuticals International Inc (VRX)” was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://theenterpriseleader.com/2018/04/02/prime-capital-investment-advisors-llc-takes-142000-position-in-valeant-pharmaceuticals-intl-inc-vrx.html.

Valeant Pharmaceuticals International Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply